Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H10O4 |
Molecular Weight | 182.1733 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCOC(=O)C1=C(O)C=CC=C1
InChI
InChIKey=LVYLCBNXHHHPSB-UHFFFAOYSA-N
InChI=1S/C9H10O4/c10-5-6-13-9(12)7-3-1-2-4-8(7)11/h1-4,10-11H,5-6H2
DescriptionSources: http://www.salonpas.sg/products/list003.htmlCurator's Comment: Description was created based on several sources, including http://www.genome.jp/dbget-bin/www_bget?dr:D01557
Sources: http://www.salonpas.sg/products/list003.html
Curator's Comment: Description was created based on several sources, including http://www.genome.jp/dbget-bin/www_bget?dr:D01557
Glycol Salicylate is a nonsteroidal antiinflammatory drug, it is an ingredient of many rubefacient creams and sprays for the relief of aches, pains and stiffness in muscles joints and tendons. It is an analgesic and anti-inflammatory agent, used topically. It is also included in preparations for soothing haemorrhoids. Glycol Salicylate is a component of Salonsip Gel Patch. Salonsip Gel Patch, manufactured by Hisamitsu Pharmaceutical Co., Inc. of Tosu City, Japan, consists of Glycol Salicylate 1.25%, l-menthol 1.00%, Tocopherol Acetate 1.0%, dl-camphor 0.1%.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Salonsip Gel-Patch Approved UseFor relief of aches, pains and minor inflammations associated with:
■ muscle fatigue
■ muscle pain
■ stiff shoulder
■ simple backache
■ bruises
■ sprains
■ strains
■ arthritis
■ minor frostbite |
|||
Palliative | Percutalgine Approved UseFor treatment of benign joint conditions such as mild tendinitis, small joint arthritis and sprains. |
Doses
Dose | Population | Adverse events |
---|---|---|
10 % 1 times / day single, topical Studied dose Dose: 10 %, 1 times / day Route: topical Route: single Dose: 10 %, 1 times / day Sources: |
healthy, 47 years n = 1 Health Status: healthy Age Group: 47 years Sex: M Population Size: 1 Sources: |
Other AEs: Contact dermatitis... Other AEs: Contact dermatitis Sources: |
5 % multiple, topical Studied dose |
unhealthy, 64 years n = 1 Health Status: unhealthy Condition: cervical pain Age Group: 64 years Sex: M Population Size: 1 Sources: |
Other AEs: Contact dermatitis... |
12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Co-administed with:: arnica tincture(41.5 mg; 5/day; during 10 days) Sources: |
unhealthy, mean age 30.8 years n = 228 Health Status: unhealthy Condition: ankle joint distortion Age Group: mean age 30.8 years Sex: M+F Population Size: 228 Sources: |
Disc. AE: Urticaria, Skin irritation... Other AEs: Redness, Itching... AEs leading to discontinuation/dose reduction: Urticaria (0.4%) Other AEs:Skin irritation (0.4%) Redness (1.7%) Sources: Itching (1.7%) Urticaria (1.7%) |
12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Sources: |
unhealthy, mean age 30.8 years n = 228 Health Status: unhealthy Condition: ankle joint distortion Age Group: mean age 30.8 years Sex: M+F Population Size: 228 Sources: |
Disc. AE: Urticaria, Redness... AEs leading to discontinuation/dose reduction: Urticaria (0.4%) Sources: Redness (0.4%) Allergic reaction (0.4%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Contact dermatitis | 10 % 1 times / day single, topical Studied dose Dose: 10 %, 1 times / day Route: topical Route: single Dose: 10 %, 1 times / day Sources: |
healthy, 47 years n = 1 Health Status: healthy Age Group: 47 years Sex: M Population Size: 1 Sources: |
|
Contact dermatitis | 5 % multiple, topical Studied dose |
unhealthy, 64 years n = 1 Health Status: unhealthy Condition: cervical pain Age Group: 64 years Sex: M Population Size: 1 Sources: |
|
Skin irritation | 0.4% Disc. AE |
12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Co-administed with:: arnica tincture(41.5 mg; 5/day; during 10 days) Sources: |
unhealthy, mean age 30.8 years n = 228 Health Status: unhealthy Condition: ankle joint distortion Age Group: mean age 30.8 years Sex: M+F Population Size: 228 Sources: |
Urticaria | 0.4% Disc. AE |
12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Co-administed with:: arnica tincture(41.5 mg; 5/day; during 10 days) Sources: |
unhealthy, mean age 30.8 years n = 228 Health Status: unhealthy Condition: ankle joint distortion Age Group: mean age 30.8 years Sex: M+F Population Size: 228 Sources: |
Itching | 1.7% | 12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Co-administed with:: arnica tincture(41.5 mg; 5/day; during 10 days) Sources: |
unhealthy, mean age 30.8 years n = 228 Health Status: unhealthy Condition: ankle joint distortion Age Group: mean age 30.8 years Sex: M+F Population Size: 228 Sources: |
Redness | 1.7% | 12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Co-administed with:: arnica tincture(41.5 mg; 5/day; during 10 days) Sources: |
unhealthy, mean age 30.8 years n = 228 Health Status: unhealthy Condition: ankle joint distortion Age Group: mean age 30.8 years Sex: M+F Population Size: 228 Sources: |
Urticaria | 1.7% | 12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Co-administed with:: arnica tincture(41.5 mg; 5/day; during 10 days) Sources: |
unhealthy, mean age 30.8 years n = 228 Health Status: unhealthy Condition: ankle joint distortion Age Group: mean age 30.8 years Sex: M+F Population Size: 228 Sources: |
Allergic reaction | 0.4% Disc. AE |
12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Sources: |
unhealthy, mean age 30.8 years n = 228 Health Status: unhealthy Condition: ankle joint distortion Age Group: mean age 30.8 years Sex: M+F Population Size: 228 Sources: |
Redness | 0.4% Disc. AE |
12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Sources: |
unhealthy, mean age 30.8 years n = 228 Health Status: unhealthy Condition: ankle joint distortion Age Group: mean age 30.8 years Sex: M+F Population Size: 228 Sources: |
Urticaria | 0.4% Disc. AE |
12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Sources: |
unhealthy, mean age 30.8 years n = 228 Health Status: unhealthy Condition: ankle joint distortion Age Group: mean age 30.8 years Sex: M+F Population Size: 228 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Contact dermatitis from anti-inflammatory gel containing hydroxyethyl salicylate. | 2002 Aug |
|
Synergetic analgesic effect of the combination of arnica and hydroxyethyl salicylate in ethanolic solution following cutaneous application by transcutaneous electrostimulation. | 2003 |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.salonpas.sg/products/list003.html
Adults and children 12 years of age and over:
clean and dry affected area. Remove from backing film and apply to affected area not more than 3 to 4 times daily. Remove after at most 8 hours.
Route of Administration:
Topical
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
87-28-5
Created by
admin on Fri Dec 15 15:04:00 GMT 2023 , Edited by admin on Fri Dec 15 15:04:00 GMT 2023
|
PRIMARY | |||
|
3269
Created by
admin on Fri Dec 15 15:04:00 GMT 2023 , Edited by admin on Fri Dec 15 15:04:00 GMT 2023
|
PRIMARY | |||
|
86541
Created by
admin on Fri Dec 15 15:04:00 GMT 2023 , Edited by admin on Fri Dec 15 15:04:00 GMT 2023
|
PRIMARY | |||
|
201-737-2
Created by
admin on Fri Dec 15 15:04:00 GMT 2023 , Edited by admin on Fri Dec 15 15:04:00 GMT 2023
|
PRIMARY | |||
|
C020904
Created by
admin on Fri Dec 15 15:04:00 GMT 2023 , Edited by admin on Fri Dec 15 15:04:00 GMT 2023
|
PRIMARY | |||
|
72097
Created by
admin on Fri Dec 15 15:04:00 GMT 2023 , Edited by admin on Fri Dec 15 15:04:00 GMT 2023
|
PRIMARY | |||
|
26051
Created by
admin on Fri Dec 15 15:04:00 GMT 2023 , Edited by admin on Fri Dec 15 15:04:00 GMT 2023
|
PRIMARY | RxNorm | ||
|
DB11323
Created by
admin on Fri Dec 15 15:04:00 GMT 2023 , Edited by admin on Fri Dec 15 15:04:00 GMT 2023
|
PRIMARY | |||
|
3I1VBB7AXH
Created by
admin on Fri Dec 15 15:04:00 GMT 2023 , Edited by admin on Fri Dec 15 15:04:00 GMT 2023
|
PRIMARY | |||
|
SUB13999MIG
Created by
admin on Fri Dec 15 15:04:00 GMT 2023 , Edited by admin on Fri Dec 15 15:04:00 GMT 2023
|
PRIMARY | |||
|
6880
Created by
admin on Fri Dec 15 15:04:00 GMT 2023 , Edited by admin on Fri Dec 15 15:04:00 GMT 2023
|
PRIMARY | |||
|
DTXSID4048987
Created by
admin on Fri Dec 15 15:04:00 GMT 2023 , Edited by admin on Fri Dec 15 15:04:00 GMT 2023
|
PRIMARY | |||
|
3I1VBB7AXH
Created by
admin on Fri Dec 15 15:04:00 GMT 2023 , Edited by admin on Fri Dec 15 15:04:00 GMT 2023
|
PRIMARY | |||
|
100000089635
Created by
admin on Fri Dec 15 15:04:00 GMT 2023 , Edited by admin on Fri Dec 15 15:04:00 GMT 2023
|
PRIMARY | |||
|
m5805
Created by
admin on Fri Dec 15 15:04:00 GMT 2023 , Edited by admin on Fri Dec 15 15:04:00 GMT 2023
|
PRIMARY | Merck Index |
SUBSTANCE RECORD